← Back to patent-cliff list
Ganaxolone
Tier C — Watch / tradeGanaxolone
Purdue Pharma
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GABAAR
Brand：ZTALMY
Indications (approved)：CDKL5缺乏症, Seizure, 癫痫综合征, 婴儿痉挛
Regional status
US
Approved
2022-03-18
EU
Approved
2023-07-26
China
Approved
2024-07-09
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ganaxolone?
Approved indications include: CDKL5缺乏症, Seizure, 癫痫综合征, 婴儿痉挛.
When does the Ganaxolone patent expire?
No public expiry year is available for Ganaxolone yet; this page updates once verified.
How do I get a quote for Ganaxolone intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27